Basic Information
Zegalogue
Regulatory Information
EMEA/H/C/006214
Authorised
July 24, 2024
May 30, 2024
2
November 7, 2024
Company Information
Denmark
Novo Alle 1 DK-2880 Bagsvaerd
Novo Nordisk A/S
Drug Classification
Additional Monitoring
Active Substances Detail
dasiglucagon hydrochloride
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Zegalogue is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.
Overview Summary
Zegalogue is used for treating severe hypoglycaemia (low blood glucose levels) in adults and children from 6 years of age who have diabetes mellitus. Hypoglycaemia can occur when diabetes medicines cause glucose levels to fall too low. In severe cases, patients can faint or become unconscious, and they must be treated urgently to raise their glucose levels. Zegalogue contains the active substance dasiglucagon.